AbbVie reported $64.4B of revenue over the trailing twelve months, +10% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $64.4B (to Q2 2026). Net income: $6.31B, trailing twelve months to Q2 2026. Free cash flow: $18.2B, trailing twelve months to Q2 2026. Operating margin: 26%, trailing twelve months to Q2 2026.

ABBVAbbVie

Healthcare

$276.40+27% 1Y

$276.40

$197.3852 weeks$276.40

Latest close: a new 52-week highOct 9, 2026what changed →

ABBV as reported

AbbVie reported $64.4B of revenue over the trailing twelve months, +10% on the year before. 11 reported series are charted on this page, each one as filed.

$64.4B

Revenue, trailing twelve months · to Q2 2026 · +10% against the twelve months before

Net income: $6.31B
Net income · +68% year on year · trailing twelve months to Q2 2026
Free cash flow: $18.2B
Free cash flow · −0.16% year on year · trailing twelve months to Q2 2026
Operating margin: 26%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for ABBV, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$64.4B	+10%	Q2 2026
Net income	$6.31B	+68%	Q2 2026
EPS	$3.54	+69%	Q2 2026
Gross margin	71%	n/a	Q2 2026
Operating margin	26%	n/a	Q2 2026
Net margin	9.5%	n/a	Q2 2026
ROE	−95%	n/a	Q2 2026
ROA	3.1%	n/a	Q2 2026
ROIC	19%	n/a	Q2 2026
Free cash flow	$18.2B	−0.16%	Q2 2026
P/E	78.1	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.